BioPharmSignal logoBioPharmSignal

Biotech News

Medicenna to Present Preclinical Data on Its CD122 Superantagonist MDNA209 at The Promises of Treg and Interleukin-2 Therapies Conference

Medicenna Therapeutics Corp. (MDNA)Medicenna Therapeutics Corp.Conference / presentation

MDNA209 is a potential first-in-class engineered Superkine designed to block CD122 and simultaneously inhibit IL-2 and IL-15 signaling to modulate an overactive immune system TORONTO and HOUSTON, Oct. 22, 2026 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX:

Related news

MDNAMedicenna Therapeutics Corp.2026-10-26 12:52 EST

Medicenna Reports Potent CD122 Blockade and Extended Survival with MDNA209 in Preclinical Models of Autoimmune Disease

URGNUroGen Pharma2026-11-03 13:00 EST

UroGen Pharma to Present at the Guggenheim Securities 3rd Annual Healthcare Innovation Conference

SNDXSyndax Pharmaceuticals2026-11-04 14:01 EST

Syndax to Host ASH Investor Event in Person and via Webcast on December 14, 2026

MDNAMedicenna Therapeutics Corp.2026-11-04 12:00 EST

Medicenna Completes Phase 1/2 ABILITY-1 Enrollment and Announces Webinar to Discuss Updated MDNA11 Results with Key Opinion Leaders

COGTCogent Biosciences2026-10-27 20:01 EST

Cogent Biosciences to Participate in the Guggenheim Healthcare Innovation Conference

PRLDPrelude Therapeutics2026-10-16 20:01 EST

Prelude Therapeutics to Participate in the Chardan Healthcare Conference

BMEABiomea Fusion2026-10-12 20:30 EST

Biomea Fusion to Announce Phase I Results for BMF-650, Its Next-Generation Oral Small-Molecule GLP-1 Receptor Agonist

CHRSCoherus BioSciences, Inc.2026-10-14 20:30 EST

Coherus Oncology to Host Webcast to Disclose Interim Tagmokitug Clinical Data on October 28, 2026

CHRSCoherus BioSciences, Inc.2026-10-27 13:30 EST

Coherus to Participate in Upcoming Investor Conferences

STROSutro Biopharma2026-10-12 12:00 EST

Sutro Biopharma Announces Participation at the 17th Annual World ADC Conference

View all latest news

Medicenna Therapeutics Corp.

IL-2 Superkine Platform Medicenna Therapeutics develops engineered cytokines and fusion proteins intended to improve antitumor immune activity. Its Superkine platform modifies cytokine receptor selectivity, potency and pharmacology. MDNA11 MDNA11 is a long-acting beta-only IL-2 agonist in the Phase 1/2 ABILITY-1 study. It is being...

Recent company news

MDNAMedicenna Therapeutics Corp.2026-11-04 12:00 EST

Medicenna Completes Phase 1/2 ABILITY-1 Enrollment and Announces Webinar to Discuss Updated MDNA11 Results with Key Opinion Leaders

MDNAMedicenna Therapeutics Corp.2026-10-26 12:52 EST

Medicenna Reports Potent CD122 Blockade and Extended Survival with MDNA209 in Preclinical Models of Autoimmune Disease

MDNAMedicenna Therapeutics Corp.2026-10-22 11:00 EST

Medicenna to Present Preclinical Data on Its CD122 Superantagonist MDNA209 at The Promises of Treg and Interleukin-2 Therapies Conference

MDNAMedicenna Therapeutics Corp.2026-10-05 13:00 EST

Medicenna Announces Oral Presentation of Topline Data from the Phase 1/2 ABILITY-1 Study of MDNA11 at SITC 2026

MDNAMedicenna Therapeutics Corp.2026-10-01 23:00 EST

Medicenna Announces Results of Annual General and Special Meeting of Shareholders

Stock data

Close
—
Market cap
—
Exchange
NASDAQ
Sector
Biopharma
Location
United States